​

Atea Pharmaceuticals Stock (NASDAQ:AVIR)

ForecastOwnershipFinancialsChartTranscripts
Atea Pharmaceuticals by TradingView

Previous Close

$5.83

52W Range

$2.78 - $6.45

50D Avg

$5.02

200D Avg

$4.61

Market Cap

$454.55M

Avg Vol (3M)

$322.56K

Beta

0.28

Div Yield

-

AVIR Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Oct 30, 2020

Website

AVIR Performance

AVIR Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-180.89M$-192.95M$-164.16M
Net Income$-158.35M$-168.38M$-135.96M
EBITDA$-180.89M$-131.80M$-119.59M
Basic EPS$-1.94$-2.00$-1.63
Diluted EPS$-1.94$-2.00$-1.63

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 12, 26 | 4:30 PM
Q1 26May 12, 26 | 4:30 PM
Q4 25Mar 05, 26 | 4:30 PM

Peer Comparison

TickerCompany
ENTAEnanta Pharmaceuticals, Inc.
TRDAEntrada Therapeutics, Inc.
HUMAHumacyte, Inc.
ALLOAllogene Therapeutics, Inc.
PYXSPyxis Oncology, Inc.
ACHVAchieve Life Sciences, Inc.
VNDAVanda Pharmaceuticals Inc.
ARCTArcturus Therapeutics Holdings Inc.
VYGRVoyager Therapeutics, Inc.